Combination of Renal Angioplasty and Angiotensin-converting-enzyme Inhibitor Can Reduce Proteinuria in Patients with Bilateral Renal Artery Disease.

Abstract

Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in patients with overt proteinuria. From the renoprotective point of view, to reduce proteinuria after PTRA is an important therapeutic goal in patients with renal artery stenosis with overt proteinuria. We hereby describe two patients successfully treated by combination therapy with PTRA and administration of angiotensin-converting enzyme (ACE) inhibitor for bilateral renal artery disease with overt proteinuria.

• Authors: Hironobu Toda, Haruhito Uchida, Kazufumi Nakamura, Hidemi Takeuchi, Masaru Kinomura, Koji Nakagawa, Atsuyuki Watanabe, Toru Miyoshi, Nobuhiro Nishii, Hiroshi Morita, Jun Wada, Hiroshi Ito
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 58 Issue 13 Pg. 1917-1922 (07 01 2019) ISSN: 1349-7235 [Electronic] Japan
• PMID: 30799351 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiotensin-Converting Enzyme Inhibitors

Topics

• Aged
• Angioplasty (adverse effects, methods)
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Humans
• Male
• Proteinuria (drug therapy, etiology)
• Renal Artery Obstruction (drug therapy, surgery)
• Treatment Outcome